Covid-19 roundup: J&J plans 60,000-person PhIII for September; Peter Marks draws a red line
J&J is planning the largest Phase III trial of a Covid-19 vaccine to date, with a goal to enroll 60,000 volunteers to test its adenovirus-based shot.
The trial, whose design was posted on clinicaltrials.gov and subsequently confirmed to Endpoints News, is expected to begin in late September. Although J&J is more than a month behind Moderna and Pfizer/BioNTech, the fact that its trial involves a single-dose regimen means it doesn’t have to wait 28 days between two administrations before starting to record the effects.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.